Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication
Descripción del Articulo
Dengue is the most common vector-borne viral disease, with low fatality rate, one death per 1000 patients. Its treatment consists of hydration, rest and symptomatic treatment. Doxycycline interferes with the entry into human cells, by inhibiting the changing E protein configuration, and stopping its...
| Autor: | |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2024 |
| Institución: | Fundación Instituto Hipólito Unanue |
| Repositorio: | Diagnóstico |
| Lenguaje: | español |
| OAI Identifier: | oai:revistadiagnostico.fihu.org.pe:article/533 |
| Enlace del recurso: | https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/533 |
| Nivel de acceso: | acceso abierto |
| Materia: | Dengue proteína E doxiciclina pulsos de esteroides protein E doxycycline steroid pulses |
| id |
REVFIHU_741724973a3962ece4eda6eb34431f73 |
|---|---|
| oai_identifier_str |
oai:revistadiagnostico.fihu.org.pe:article/533 |
| network_acronym_str |
REVFIHU |
| network_name_str |
Diagnóstico |
| repository_id_str |
|
| spelling |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indicationEl dengue: Son necesarios estudios multicéntricos aleatorizados, con las medicinas que en segunda indicación podrían ser efectivasAccinelli, Roberto AlfonsoDengueproteína Edoxiciclinapulsos de esteroidesDengueprotein Edoxycyclinesteroid pulsesDengue is the most common vector-borne viral disease, with low fatality rate, one death per 1000 patients. Its treatment consists of hydration, rest and symptomatic treatment. Doxycycline interferes with the entry into human cells, by inhibiting the changing E protein configuration, and stopping its replication by acting on the NS2BNS3pro protease of the virus. Therefore, itcould be an alternative, and when the disease has reached the stage of cytokine storm, manifested by severe thrombocytopenia, hemoconcentration and systemic involvement, the use of steroid or immunoglobulin pulses could be indicated. Multicenter placebocontrolled studies are needed to demonstrate the effect of these drugs in secondary indication so that the WHO and CDC can recommend or not their use, so for now we cannot use them.El dengue es la enfermedad viral transmitida por vectores más frecuente, de baja letalidad, un fallecido por cada 1000 enfermos. Su tratamiento es con hidratación, reposo y sintomáticos. La doxiciclina, que interfiere con el ingreso a la célula humana, al impedir cambie la configuración de la proteína E, y detiene su replicación, al actuar en la proteasa NS2BNS3pro del virus, podría ser una alternativa, y cuando la enfermedad ha llegado hasta la tormenta de citoquinas, manifestada por plaquetopenia severa, hemoconcentración y compromiso sistémico, el empleo de pulsos de esteroides o de inmunoglobulinas podría estar indicado. Son necesarios estudios multicéntricos controlados contra placebo que demuestren el efecto de estas medicinas en segunda indicación para que la OMS y el CDC puedan recomendar o no su uso, por lo que por ahora no podemos emplearlos.Fundación Instituto Hipólito Unanue2024-10-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/53310.33734/diagnstico.v63i3.533Diagnóstico; Vol. 63 No. 3 (2024); e533Diagnostico; Vol. 63 Núm. 3 (2024); e5331018-28882709-795110.33734/diagnostico.v63i3reponame:Diagnósticoinstname:Fundación Instituto Hipólito Unanueinstacron:FIHUspahttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/533/509Derechos de autor 2024 Roberto Alfonso Accinellihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:revistadiagnostico.fihu.org.pe:article/5332024-11-14T19:31:00Z |
| dc.title.none.fl_str_mv |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication El dengue: Son necesarios estudios multicéntricos aleatorizados, con las medicinas que en segunda indicación podrían ser efectivas |
| title |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication |
| spellingShingle |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication Accinelli, Roberto Alfonso Dengue proteína E doxiciclina pulsos de esteroides Dengue protein E doxycycline steroid pulses |
| title_short |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication |
| title_full |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication |
| title_fullStr |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication |
| title_full_unstemmed |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication |
| title_sort |
Dengue: Randomized multicenter studies are needed with medicines that could be effective as a second indication |
| dc.creator.none.fl_str_mv |
Accinelli, Roberto Alfonso |
| author |
Accinelli, Roberto Alfonso |
| author_facet |
Accinelli, Roberto Alfonso |
| author_role |
author |
| dc.subject.none.fl_str_mv |
Dengue proteína E doxiciclina pulsos de esteroides Dengue protein E doxycycline steroid pulses |
| topic |
Dengue proteína E doxiciclina pulsos de esteroides Dengue protein E doxycycline steroid pulses |
| description |
Dengue is the most common vector-borne viral disease, with low fatality rate, one death per 1000 patients. Its treatment consists of hydration, rest and symptomatic treatment. Doxycycline interferes with the entry into human cells, by inhibiting the changing E protein configuration, and stopping its replication by acting on the NS2BNS3pro protease of the virus. Therefore, itcould be an alternative, and when the disease has reached the stage of cytokine storm, manifested by severe thrombocytopenia, hemoconcentration and systemic involvement, the use of steroid or immunoglobulin pulses could be indicated. Multicenter placebocontrolled studies are needed to demonstrate the effect of these drugs in secondary indication so that the WHO and CDC can recommend or not their use, so for now we cannot use them. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024-10-07 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/533 10.33734/diagnstico.v63i3.533 |
| url |
https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/533 |
| identifier_str_mv |
10.33734/diagnstico.v63i3.533 |
| dc.language.none.fl_str_mv |
spa |
| language |
spa |
| dc.relation.none.fl_str_mv |
https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/533/509 |
| dc.rights.none.fl_str_mv |
Derechos de autor 2024 Roberto Alfonso Accinelli https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Derechos de autor 2024 Roberto Alfonso Accinelli https://creativecommons.org/licenses/by/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Fundación Instituto Hipólito Unanue |
| publisher.none.fl_str_mv |
Fundación Instituto Hipólito Unanue |
| dc.source.none.fl_str_mv |
Diagnóstico; Vol. 63 No. 3 (2024); e533 Diagnostico; Vol. 63 Núm. 3 (2024); e533 1018-2888 2709-7951 10.33734/diagnostico.v63i3 reponame:Diagnóstico instname:Fundación Instituto Hipólito Unanue instacron:FIHU |
| instname_str |
Fundación Instituto Hipólito Unanue |
| instacron_str |
FIHU |
| institution |
FIHU |
| reponame_str |
Diagnóstico |
| collection |
Diagnóstico |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1846524449793245184 |
| score |
13.425424 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
